Search for the biomarker of the immune checkpoint inhibitor
| Project/Area Number |
17K10780
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
花岡 淳 滋賀医科大学, 医学部, 准教授 (00452243)
寺本 晃治 滋賀医科大学, 医学部, 特任講師 (10452244)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 非小細胞がん / PD-L1 / がん関連線維芽細胞 / 無再発生存期間 / 非小細胞肺がん / 免疫チェックポイント阻害薬 / バイオマーカー / 肺がん / 免疫チェックポイント |
|---|
| Outline of Final Research Achievements |
The expression of PD-L1 molecules in non-small cell lung cancer was reversibly controled by IFN γ. Furthermore, PD-L1 molecules overexpression in early non-small cell lung cancer means prolong relapse free survival, but in an advanced stage, it means shorten relapse free survival adversely. We showed the possibility that plasma PD-L1 molecules were influenced not only PD-L1 expression on lung cancer cells but also the tumor infitrated macrophages. PD-L1 overexpression of cancer-asociated fibroblasts means prolong relapse free survival and it was the independent convalescence marker for convalescence predictions.
|
| Academic Significance and Societal Importance of the Research Achievements |
非小細胞肺がんにおいて、免疫チェックポイント阻害薬を用いて治療を行う際の、治療効果予測のためのバイオマーカーを探索し、非小細胞肺がんにおけるPD-L1発現の臨床病理学的な意義について示した。
|
Report
(4 results)
Research Products
(7 results)
